BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther. 2012;14:R145. [PMID: 22697462 DOI: 10.1186/ar3879] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Cipriani P, Di Benedetto P, Dietrich H, Ruscitti P, Liakouli V, Carubbi F, Pantano I, Berardicurti O, Sgonc R, Giacomelli R. Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. Arch Med Sci 2016;12:828-43. [PMID: 27478465 DOI: 10.5114/aoms.2016.60970] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Wang H, Cui H, Lin L, Ji Y, Ni Q, Li J, Pang J, Bing G, Bian Y. The effects of a hirudin/liposome complex on a diabetic nephropathy rat model. BMC Complement Altern Med 2019;19:118. [PMID: 31170978 DOI: 10.1186/s12906-019-2531-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sanges S, Guerrier T, Launay D, Lefèvre G, Labalette M, Forestier A, Sobanski V, Corli J, Hauspie C, Jendoubi M, Yakoub-Agha I, Hatron PY, Hachulla E, Dubucquoi S. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne 2017;38:113-24. [PMID: 27020403 DOI: 10.1016/j.revmed.2016.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
4 Wang Y, Yang Y, Luo Y, Yin Y, Wang Q, Li Y, Kanekura T, Wang J, Liang G, Zhao M, Lu Q, Xiao R. Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis. Clin Immunol 2013;149:46-54. [PMID: 23891737 DOI: 10.1016/j.clim.2013.06.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
5 Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmun Rev 2016;15:155-61. [PMID: 26497107 DOI: 10.1016/j.autrev.2015.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
6 Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016;18:118. [PMID: 27208972 DOI: 10.1186/s13075-016-1017-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
7 Moazedi-fuerst F, Kielhauser S, Hermann J, Meilinger M, Demel U, Stradner M, Graninger W. Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy? Scandinavian Journal of Rheumatology 2015;44:519-20. [DOI: 10.3109/03009742.2015.1069888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Antonopoulos I, Daoussis D, Lalioti ME, Markatseli TE, Drosos AA, Taraviras S, Andonopoulos AP, Liossis SC. B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis. Rheumatol Int 2019;39:1889-98. [PMID: 31227855 DOI: 10.1007/s00296-019-04350-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019;78:979-87. [PMID: 30967395 DOI: 10.1136/annrheumdis-2018-214816] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 34.5] [Reference Citation Analysis]
10 Stasi C, Triboli E, Arena U, Urraro T, Petrarca A, Gragnani L, Laffi G, Zignego AL. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med. 2014;12:21. [PMID: 24456582 DOI: 10.1186/1479-5876-12-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
11 Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmunity Reviews 2018;17:582-7. [DOI: 10.1016/j.autrev.2017.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
12 Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int Immunopharmacol 2021;95:107524. [PMID: 33721757 DOI: 10.1016/j.intimp.2021.107524] [Reference Citation Analysis]
13 Klavdianou K, Liossis SN, Sakkas L, Daoussis D. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 2017;46:430-8. [PMID: 27670695 DOI: 10.1016/j.semarthrit.2016.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
14 Iwayama T, Olson LE. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Curr Rheumatol Rep 2013;15:304. [PMID: 23307576 DOI: 10.1007/s11926-012-0304-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
15 Worrell JC, O'Reilly S. Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 2020;113:102526. [PMID: 32713676 DOI: 10.1016/j.jaut.2020.102526] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
16 Mcqueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology 2015;54:757-67. [DOI: 10.1093/rheumatology/keu463] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
17 Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 [DOI: 10.5499/wjr.v3.i2.9] [Reference Citation Analysis]
18 Ntelis K, Solomou EE, Sakkas L, Liossis SN, Daoussis D. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Semin Arthritis Rheum 2017;47:409-17. [PMID: 28602360 DOI: 10.1016/j.semarthrit.2017.05.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
19 Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int 2020;40:679-94. [PMID: 31960079 DOI: 10.1007/s00296-020-04515-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
20 Sacchetti C, Bottini N. Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets. Curr Rheumatol Rep 2017;19:28. [PMID: 28397126 DOI: 10.1007/s11926-017-0655-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis. J Invest Dermatol 2017;137:1671-81. [PMID: 28433542 DOI: 10.1016/j.jid.2017.03.032] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
22 Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 2018;57:2106-13. [DOI: 10.1093/rheumatology/key213] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 27.7] [Reference Citation Analysis]